Related news from
Fri, 31 Oct 2025 14:15:00 +0000	Prescription for Beats: 3 Healthcare Stocks Set to Outperform in Q3 Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.
Fri, 31 Oct 2025 13:15:03 +0000	Countdown to Cencora (COR) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS Evaluate the expected performance of Cencora (COR) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Fri, 31 Oct 2025 13:00:36 +0000	Stocks making big moves this week: Cencora, Custom Truck One Source, Kirby, Mister Car Wash, and Cardinal Health Check out the companies making headlines this week:
Thu, 30 Oct 2025 19:36:16 +0000	Cencora (COR) Stock Is Up, What You Need To Know Shares of healthcare distributor Cencora (NYSE:COR) jumped 3.3% in the morning session after Mizuho analyst Steven Valiquette raised the price target on the company's shares. The price target was increased to $340 from $334, while the firm kept an 'Outperform' rating on the stock. This move signaled continued confidence in Cencora's market performance. Adding to the positive mood in the sector, a key peer, Cardinal Health, reported strong quarterly results and lifted its outlook for the year. Ca
Thu, 30 Oct 2025 14:00:43 +0000	Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy? Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wed, 29 Oct 2025 14:00:34 +0000	Cencora (COR) Earnings Expected to Grow: Should You Buy? Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wed, 29 Oct 2025 13:45:03 +0000	Why Cencora (COR) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Tue, 28 Oct 2025 13:40:03 +0000	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tue, 28 Oct 2025 13:16:00 +0000	Baxter Q3 Preview: Can Core Segments Deliver Another Solid Quarter? Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.
Tue, 28 Oct 2025 12:05:00 +0000	United State Cell and Gene Therapy Third-Party Logistics Market Analysis Report 2025-2033: Expansion Fueled by Rising R&D Expenditure, Regulatory Complexity, & Strong Demand from Major Biopharma Hubs The U.S. Cell and Gene Therapy Third-Party Logistics (3PL) Market is anticipated to surge from US$ 2.61 billion in 2024 to US$ 5.88 billion by 2033, maintaining a CAGR of 9.46% from 2025 to 2033. Key growth drivers include increased therapy adoption, specialized logistics needs, and expanding biopharmaceutical collaborations. Regulatory demands, cold chain technology adoption, and challenges such as logistics costs and workforce expertise underscore the market's evolution. States like California
Mon, 27 Oct 2025 06:12:00 +0000	World-Renowned Surgeon and Entrepreneur Dr. Mandeep S. Dhalla Invests in DentScribe.ai and Joins as Strategic Advisor DentScribe.ai, the agentic AI platform that transforms dental SOAP notes into real-time clinical checklists and practice growth signals, today announced that Dr. Mandeep S. Dhalla, MD, has invested in the company and joined as a Strategic Advisor.
Sun, 26 Oct 2025 20:08:05 +0000	A Fresh Look at Cencora (COR) Valuation as Shares Rally 8% in the Past Month Cencora (COR) shares continue to climb, gaining around 1% in the past day and up over 8% for the month. Investors seem to be weighing the company’s strong revenue and net income growth in light of broader market trends. See our latest analysis for Cencora. Cencora’s momentum is clearly building, with a 1-month share price return of 8% and the stock now up over 48% year to date. Its 1-year total shareholder return of 43% is even more impressive, reinforcing both near-term optimism and the...
Fri, 24 Oct 2025 12:58:00 +0000	Pharma, Specialty Units Likely to Drive Cardinal Health's Q1 Earnings CAH's Pharmaceutical and Specialty units are expected to have fueled double-digit revenue growth in Q1 FY26 despite tariff and cost headwinds.
Wed, 22 Oct 2025 13:21:00 +0000	Universal Health to Report Q3 Earnings: Key Estimates to Note UHS is likely to have posted Q3 revenue and earnings growth, driven by strong hospital and behavioral health segments despite cost pressures.
Wed, 22 Oct 2025 13:13:29 +0000	What to Expect From Cencora's Q4 2025 Earnings Report Cencora is scheduled to release its fourth-quarter results next month, with analysts projecting double-digit earnings growth.
Tue, 21 Oct 2025 16:10:03 +0000	Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report? Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Sun, 19 Oct 2025 02:07:37 +0000	How McKesson’s (MCK) Exclusive PHYRAGO Distribution Could Shape Its Specialty Pharma Growth Trajectory Earlier this week, Cycle Pharmaceuticals announced the launch of PHYRAGO, a new oncology therapy for leukemia, developed with Handa Therapeutics and made exclusively available in the US through Onco360® and a specialty distribution network that includes McKesson. This collaboration provides McKesson with a valuable commercial opportunity as an exclusive distributor for a newly introduced specialty oncology product in high-need therapeutic areas. We'll explore how McKesson's participation in...
Thu, 16 Oct 2025 13:00:00 +0000	Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US DETROIT, October 16, 2025--Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in partnership with Handa Therapeutics, LLC, and will be exclusively available through specialty pharmacy Onco360® with a specialty distribution network from McKesson, Cencora, and Cardinal Health.
Thu, 16 Oct 2025 13:00:00 +0000	IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes CONSHOHOCKEN, Pa., October 16, 2025--IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina and other therapeutic areas. As part of this expansion, IntrinsiQ is now also offering oncology biomarker data, enabling physicians to transition from a generalized treatment approach to precision medicine. This critical data allows physicians to tailor cancer therapies to the individual needs of e
Tue, 14 Oct 2025 16:47:00 +0000	The Market Took a Hit. These 6 Stocks Can Sidestep the Wreckage. Those looking to buy stocks right now should look for the ones that aren’t correlated to the artificial intelligence trade.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!